BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29125676)

  • 1. Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States.
    Kwong A; Kim WR; Mannalithara A; Heo NY; Udompap P; Kim D
    Liver Transpl; 2018 Jun; 24(6):735-743. PubMed ID: 29125676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intention-to-treat survival analysis of hepatitis C virus/human immunodeficiency virus coinfected liver transplant: Is it the waiting list?
    Araiz JJ; Serrano MT; García-Gil FA; Lacruz EM; Lorente S; Sánchez JI; Suarez MA
    Liver Transpl; 2016 Sep; 22(9):1186-96. PubMed ID: 27114030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates.
    Gadiparthi C; Cholankeril G; Perumpail BJ; Yoo ER; Satapathy SK; Nair S; Ahmed A
    World J Gastroenterol; 2018 Jan; 24(3):315-322. PubMed ID: 29391754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.
    Young K; Liu B; Bhuket T; Gish RG; Wong RJ
    J Viral Hepat; 2019 Mar; 26(3):350-361. PubMed ID: 30412318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation.
    Wong RJ; Gish RG; Ahmed A
    Liver Transpl; 2014 Dec; 20(12):1454-61. PubMed ID: 25155379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.
    Somsouk M; Kornfield R; Vittinghoff E; Inadomi JM; Biggins SW
    Liver Transpl; 2011 Feb; 17(2):129-36. PubMed ID: 21280185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wait-list mortality of young patients with Biliary atresia: Competing risk analysis of a eurotransplant registry-based cohort.
    van der Doef HPJ; van Rheenen PF; van Rosmalen M; Rogiers X; Verkade HJ;
    Liver Transpl; 2018 Jun; 24(6):810-819. PubMed ID: 29377411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
    Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
    Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
    Crespo G; Trota N; Londoño MC; Mauro E; Baliellas C; Castells L; Castellote J; Tort J; Forns X; Navasa M
    J Hepatol; 2018 Jul; 69(1):11-17. PubMed ID: 29481821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waiting list mortality of patients with primary biliary cirrhosis in the Japanese transplant allocation system.
    Genda T; Ichida T; Sakisaka S; Sata M; Tanaka E; Inui A; Egawa H; Umeshita K; Furukawa H; Kawasaki S; Inomata Y
    J Gastroenterol; 2014 Feb; 49(2):324-31. PubMed ID: 23478939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.
    Kwong AJ; Lai JC; Dodge JL; Roberts JP
    Liver Transpl; 2015 Nov; 21(11):1403-9. PubMed ID: 26289624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of diabetes and acute rejection on liver transplant outcomes: An analysis of the organ procurement and transplantation network/united network for organ sharing database.
    Kuo HT; Lum E; Martin P; Bunnapradist S
    Liver Transpl; 2016 Jun; 22(6):796-804. PubMed ID: 26850091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation.
    Leise MD; Kim WR; Kremers WK; Larson JJ; Benson JT; Therneau TM
    Gastroenterology; 2011 Jun; 140(7):1952-60. PubMed ID: 21334338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10-Year united network for organ sharing review of mortality and risk factors in young children awaiting liver transplantation.
    Leung DH; Narang A; Minard CG; Hiremath G; Goss JA; Shepherd R
    Liver Transpl; 2016 Nov; 22(11):1584-1592. PubMed ID: 27541809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
    Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
    Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates.
    Sharma P; Schaubel DE; Gong Q; Guidinger M; Merion RM
    Hepatology; 2012 Jan; 55(1):192-8. PubMed ID: 21898487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of recurrent hepatitis C virus after liver transplantation.
    Jiménez-Pérez M; González-Grande R; Rando-Muñoz FJ
    World J Gastroenterol; 2014 Nov; 20(44):16409-17. PubMed ID: 25469009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.